INTRODUCTION
Microglia are resident myeloid-lineage cells in the parenchyma of the central nervous system (CNS) that play essential roles in the maintenance of homeostasis and responses to infection and injury Ransohoff and Perry, 2009; Streit, 2002) . Under normal conditions, microglia are maintained in a quiescent state by neuron and astrocyte-derived factors (Cardona et al., 2006) , and constantly survey the surrounding environment through an extensive array of ramified processes (Nimmerjahn et al., 2005) . Upon detection of microbial invasion or evidence of tissue damage, microglia rapidly initiate an inflammatory response that serves to recruit the immune system and tissue repair processes. Microglia sense infection and injury through numerous pattern recognition receptors, such as toll-like receptors (TLR) , that regulate the activities of NF-kB, AP-1 and other signal-dependent transcription factors (Akira et al., 2006) . These transcription factors act in a combinatorial manner to induce a robust program of gene expression that initiates innate and adaptive immune responses (Vallabhapurapu and Karin, 2009) . Astrocytes also sense infection and injury, and amplify the immune reaction initiated by microglia (Saijo et al., 2009; Sofroniew and Vinters, 2010) . Microglia/astrocyte activation is required for effective immune responses, but the inflammatory program that is induced by these cells also has the potential to cause neuronal dysfunction and death if inflammatory responses are not properly resolved. Deregulation of inflammatory responses by microglia and astrocytes has been suggested to contribute to the severity of several neurodegenerative diseases, including Parkinson's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, HIV-associated dementia and Multiple Sclerosis (MS) Perry et al., 2010; Yadav and Collman, 2009; Tiwari-Woodruff et al., 2007) .
Estrogens and synthetic estrogen receptor (ER) ligands have been documented to exert anti-inflammatory effects in animal models for MS , suggesting that estrogen receptors may participate in physiological regulation of inflammation. Roles of estrogens and their receptors in the brain are particularly complex. Two members of the nuclear receptor superfamily, estrogen receptor (ER), ERa (NR3A1) and ERb (NR3A2), bind to 17b-estradiol and activate estrogen-regulated target genes (Kuiper et al., 1996; Chang et al., 2008) . ERa is highly expressed in female reproductive organs and plays major roles in mediating the reproductive and sexually dimorphic effects of estrogens in females. ERb also regulates reproductive functions, but exhibits a distinct pattern of expression. Both ERb and ERa are expressed in the brain, with differential levels of expression observed in specific regions (Kuiper et al., 1997; Laflamme et al., 1998) . The relative expression levels and functions of ERa and ERb in specific subsets of microglia, astrocytes and neurons have not been established.
Although the DNA binding domains (DBDs) of ERa and ERb are highly conserved (98% identity in human), their ligand-binding domains (LBDs) exhibit less conservation (59% identity in human), and ERb binds selectively a distinct spectrum of naturally occurring as well as synthetic and plant-derived steroids (Kuiper et al., 1997) . Consistent with this, it has been possible to develop synthetic ligands that exhibit preferential affinity for ERa or ERb (Minutolo et al., 2009) . Anti-inflammatory effects of estrogens and ER-selective ligands within the CNS have been extensively evaluated in the context of experimental autoimmune encephalomyelitis (EAE), an animal model of MS Tiwari-Woodruff et al., 2007; Vegeto et al., 2000) . Therapeutic mechanisms include anti-inflammatory effects in antigen presenting cells as well as neurotrophic effects. Estrogen represses several proinflammatory mediators including cytokines, chemokines, and matrix metalloproteinase-9 in dendritic cells ) and in microglia (Vegeto et al., 2000) . The protective effect of estrogen requires ERa, since it is not observed in ERa knockout mice . However, treatment with the ERb-selective ligand 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) was also recently shown to be protective in the EAE model (Tiwari-Woodruff et al., 2007) . This effect was not associated with anti-inflammatory activity, but rather was proposed to be due to ERb ligands acting on neurons to promote survival and preserve myelination.
Here, we report that synthetic ERb-specific ligands based on a halogen-substituted phenyl-2H-indazole core (referred to hereafter as Indazole-Br and Indazole-Cl) (De Angelis et al., 2005) potently inhibit transcriptional activation of inflammatory response genes in microglia and astrocytes. This observation led to the identification of an ERb-specific transrepression pathway that we propose is controlled endogenously by regulated production of 5-androsten-3b,17b-diol (ADIOL). 17b -hydroxysteroid dehydrogenase type 14 (HSD17B14), a member of HSD17B-family, converts 5-androsten-3b-ol-17-one (dehydroepiandrosterone, DHEA) to ADIOL, and the expression of HSD17B14 itself is controlled by inducers and inhibitors of inflammatory responses. Lack of this enzyme or ERb results in exaggerated inflammatory responses in microglia and astrocytes. These findings suggest that an ADIOL-ERb-CtBP repression pathway may play roles in the maintenance of CNS homeostasis by regulating the magnitude and duration of inflammatory responses.
RESULTS

A Subset of ERb-Specific Ligands Inhibit Inflammatory Responses in Microglia
Quantitative analysis of nuclear receptor expression in primary mouse and human microglia indicated high levels of ERb transcripts and relatively low levels of ERa transcripts (Figures S1A and S1B available online). The murine BV2 microglia cell line selectively expressed ERb ( Figure S1C ), in agreement with a previous report (Baker et al., 2004) . Taking advantage of BV2 cells, we first tested several ERb-specific synthetic ligands for their effects on LPS-dependent activation of the inducible nitric oxide synthase (iNOS) gene. Notably Indazole-Br and IndazoleCl ( Figure S1D ) (De Angelis et al., 2005) significantly repressed the induction of iNOS mRNA, while 17b-estradiol (E2), the ERa selective agonist 4,4',4''-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) (Stauffer et al., 2000) , and the structurally distinct ERb-specific ligands DPN (Meyers et al., 2001 ) and ERB-041 (Malamas et al., 2004) did not ( Figure 1A ). Knockdown of ERb expression using a specific small inhibitory RNA (siRNA) abolished the Indazole-Cl-mediated repression of iNOS mRNA expression upon LPS stimulation ( Figure 1B and Figure S1E ). In addition, Indazoles did not repress LPS-induced iNOS expression in mouse RAW264.7 macrophages that selectively express ERa ( Figures S1C and S1F ). These results indicate that IndazoleBr-and Indazole-Cl-mediated repression is ERb-dependent.
Several lines of evidence suggest that Th17 T cells play essential roles in focal autoimmune diseases including MS (Korn et al., 2009; Littman and Rudensky, 2010) . The differentiation and activation of Th17 T cells requires specific combinations of cytokines provided by antigen presenting cells such as Transforming growth factor (TGF)b, interleukin (IL)-6, IL-1b and IL-23 for mice (Ghoreschi et al., 2010; Korn et al., 2009; Littman and Rudensky, 2010) . Since microglia have been suggested to perform an essential role in the onset of EAE (Heppner et al., 2005) and estrogen played important roles to modify MS/EAE Vegeto et al., 2008) , we tested whether Indazole-Br and Indazole-Cl could repress those cytokines required for the differentiation and activation of Th17 T cells. In BV2 cells, Indazole-Br and Indazole-Cl significantly repressed the mRNA expression of IL-23p19 ( Figure 1C ), IL-6 ( Figure 1D ), and IL-1b ( Figure 1E ) that are required for the differentiation and activation of Th17 T cells, but not TGFb, which is important also for the differentiation of anti-inflammatory regulatory T cells (Tregs) (Figure 1F ) (Littman and Rudensky, 2010) . Indazole-Cl repressed IL-6 expression with an EC 50 value of $30-100 nM in BV2 cells ( Figure S1G ). Similarly, Indazole-Br and Indazole-Cl repressed IL-23p19 and IL-6 in primary mouse microglia cells (Figures S1H and S1I). It was reported that IL-1b, but not IL-6, is required for the differentiation of human Th17 cells (Acosta-Rodriguez et al., 2007; Wilson et al., 2007) . Therefore, we also tested whether the Indazoles repressed these cytokines in human microglia cells. Indazoles significantly repressed the mRNA expression of IL-1b ( Figure 1G ) and IL-23p19 ( Figure 1H ) to a greater extent than 17b-estradiol. In contrast, 17b-estradiol, but not Indazoles, suppressed expression of TGFb in human primary microglia ( Figure S1J ). Next, we tested ERb-dependency of Indazole-mediated repression of IL-1b, using siRNAs specific for ERb and ERa. Transfection of siRNAs specifically targeting ERb abolished Indazole-Cl-mediated repression of IL-1b ( Figure S1K-M) . In contrast, transfection of siRNAs against ERa did not show any reversal of Indazole-Cl-mediated repression. Thus, Indazole-Cl-mediated repression of proinflammatory genes in human microglia cells is also mediated by ERb.
Finally, we measured cytokine secretion by mouse and human microglia cells by ELISA. Consistent with mRNA data, the production of IL-6 and IL-23 were strongly induced by LPS stimulation, and both Indazole-Br and Indazole-Cl significantly inhibited their secretion ( Figures 1I and 1J) , with corresponding effects on IL-1b in human microglia ( Figure 1K ). These data indicate that, in contrast to 17b-estradiol, Indazole-Br and IndazoleCl act to strongly suppress the production of proinflammatory mediators in response to LPS, including those required for the differentiation and activation of Th17 T cells.
A Subset of ERb-Specific Ligands Inhibit Inflammatory Responses in Astrocytes
Astrocytes also contribute to inflammatory responses and have been reported to be a major source of BAFF (also known as BLyS/TNFSF13B) (Krumbholz et al., 2005) , which supports the survival of potential auto-reactive B cells (Mackay and Browning, 2002) . Since both human and mouse primary astrocytes express high levels of ERb ( Figure S2A and B), we next examined whether the Indazoles repressed inflammatory responses in these cells. Activated mouse and human astrocytes upregulated mRNA expression of BAFF when stimulated by IL-1b, consistent with previous reports, and Indazole-Br and Indazole-Cl, but not 17b-estradiol, significantly repressed this response (Figures 2A  and 2D ). Similarly, Indazole-Br and Indazole-Cl suppressed IL1b-induced expression of IL-23p19 and iNOS mRNAs in mouse and human astrocytes ( Figures 2B, 2C , 2E, and 2F). Although, the Figure S1 .
expression of ERa in astrocytes is significantly lower than ERb, we confirmed that Indazole-mediated repression was indeed ERb-dependent by knocking down ERa or ERb expression using specific siRNAs ( Figure S2C ). As shown in Figure 2G , knockdown of ERb expression, but not ERa expression, reverted IndazoleCl-mediated repression of BAFF mRNA expression. Notably, siRNA knockdown of ERb resulted in a marked increase in induced BAFF expression. Finally, the Greiss reaction was used to determine effects of ERb ligands on IL-1b-induced NO production. Indazole-Br and Indazole-Cl, but not 17b-estradiol, inhibited IL-1b-induced production of NO in human astrocytes ( Figure 2H ).
Synthetic and Endogenous ERb Modulators Prevent EAE in Mice
To determine whether Indazoles could inhibit inflammation in the brain, we monitored the effect of Indazole-Cl treatment on the expression of proinflammatory genes in the substantia nigra following injection of LPS into the peritoneal cavity ( Figure 3A ), which induces both systemic and CNS inflammation (Bhaskar et al., 2010) . Indazole-Cl treatment suppressed induction of IL-6 in the substantia nigra ( Figure 3A ), but did not suppress iNOS induction in the bone marrow ( Figure S3A ), consistent with high expression of ERb in microglia and astrocytes, but low expression in myeloid cells. Based on the ability of IndazoleBr and Indazole-Cl to repress induction of factors in microglia that promote Th17 T cell differentiation and activation, and the established roles of microglia in the onset of EAE (Heppner et al., 2005) , we also evaluated effects of Indazole-Cl on development of EAE. Female C57BL/6 mice (WT mice) without oophorectomy were immunized with MOG35-55 peptide in the presence of complete Freund adjuvant and pertusis toxin, following an aggressive protocol (Stromnes and Goverman, 2006) . After about 3 weeks of immunization with peptide, mice treated with ethanol (vehicle) showed severe signs of EAE. In contrast, Indazole-Cl treated mice showed no obvious signs or limited paralysis only in tails ( Figure 3B ). The therapeutic effect of Indozole-Cl required ERb, as it had no effect on the severity of EAE in ERb À/À mice ( Figure 3B ). Consistent with in vitro data ( Figure 1 and Figure 2 ), Indazole-Cl treatment of WT EAE-induced mice resulted in the reduction of Th17 T cells ( Figure S3B ). Although ERb À/À mice did not exhibit more severe disease than WT mice in these studies, the aggressive immunization protocol might have precluded measurement of a difference in sensitivity.
To address this possibility, a second series of studies was performed using a less aggressive immunization protocol that produced mild tail paralysis in WT animals. In these experiments, ERb À/À mice still developed severe disease, indicating that loss of ERb increases susceptibility to EAE ( Figure S3C ). Finally, to test the potential clinical utility of Indazole-Cl treatment, studies were performed using the aggressive immunization protocol in which treatment was not initiated until after animals exhibited signs of disease (approximate clinical score of 1) ( Figure 3C ). Both Indazole-Cl-treated and vehicle-treated animals continued to worsen for the next three to four days. Thereafter, treated animals exhibited significant improvement, while untreated animals developed increasingly severe disease, indicating that Indazole-Cl can promote resolution of established inflammation after it has been established.
ADIOL Is an Endogenous ERb Ligand and Controls Inflammation in Microglia
Although 17b-estradiol binds to ERb and stimulates its transcriptional activities on positively regulated genes (Kuiper et al., 1996) it was much less effective at inhibiting inflammatory responses than Indazole-Br or Indazole-Cl. This observation raised the question of whether endogenous steroids other than 17b-estradiol might act similarly to Indazole-Br or Indazole-Cl to effect ERb-mediated repression of inflammatory response genes in microglia and astrocytes. To address this question, we screened a panel of naturally occurring steroids reported to bind ERb (Kuiper et al., 1997) for the ability to suppress induction of IL-6 in microglia upon LPS stimulation ( Figure 3D ) as well as synthetic or plant plant-derived steroids ( Figure S3D ). Although most of these molecules had no activity, ADIOL (5-androstene-3b,17b-diol), the synthetic ligand 4-estren-17b-ol-3-one (19-nortestosterone) and the nonsteroidal ligand coumestrol exerted substantial repressive effects, while DHEA (5-androsten-3b-ol-17-one, dehydroepiandrosterone) and 5a-androstan-3b,17b-diol had weak activity.
We focused our attention on ADIOL ( Figure 3E ) because it can be generated from its precursor DHEA in microglia by reduction of the 17 keto group (Jellinck et al., 2007) . In addition to suppressing activation of IL-6, ADIOL also inhibited the expression of IL-1b upon LPS stimulation of human microglia ( Figure S3E ), and the expression of iNOS mRNA in mouse astrocytes when cells were stimulated by IL-1b ( Figure S3F ). In microglia, ADIOL repressed induction of IL-6 mRNA transcription with an IC 50 of $30-100 nM ( Figure S3G ). ADIOL-mediated repression of inflammation was dependent on ERb, since siRNA against ERb abolished the repression of IL-23p19 in microglia ( Figure S3H ). ADIOL also repressed the expression of IL-6 in the substantia nigra following LPS injection into peritoneal cavity, indicating that ADIOL can repress microglia-mediated inflammation in vivo ( Figure 3F ). Next we evaluated the ability of ADIOL to repress the signs of EAE. Although less efficacious than Indazole-Cl, ADIOL also suppressed signs of EAE in an ERb-dependent manner ( Figure 3G ). These findings suggest that ADIOL is a steroid with ERb-modulatory activities similar to those of Indazole-Cl and Indazole-Br.
Regulated Production of ADIOL by HSD17B14
The conversion of DHEA to ADIOL requires the enzymatic activities of 17b-hydroxysteroid dehydrogenases (17b-HSD, HSD17B) ( Figure 4A ) (Moeller and Adamski, 2009 ADIOL (Lin et al., 2006) . However, there are at least 14 different members of the 17b-HSD family identified in humans and mice, and some of them could also potentially convert DHEA to ADIOL (Moeller and Adamski, 2009) . ADIOL is converted by 3b-hydroxysteroid dehydrogenase/D 5 , D 4 isomerase (3b-HSD, HSD3B) to testosterone, and finally to estradiol by aromatase ( Figure 4A ) 9.5 9.7 9.9 10.1 9.5 9.7 9.9 10.1 9.5 9.7 9. COS-1 cells were transfected with the indicated expression vectors, using HSD17B1 as a positive control, and the products of DHEA conversion were monitored by gas chromatography at 0, 1 and 6 hr. Retention times for DHEA and ADIOL standards are indicated.
(C) Knockdown of HSD17B14 in BV2 cells by stable transduction with a lentiviral vector directing expression of a specific shRNA inhibits conversion of DHEA to ADIOL. ADIOL levels in media were quantified 24 hr after addition of DHEA. (D). Stable knockdown of HSD17B14 using two different shRNAs blocks the ability of DHEA, but not ADIOL or Indazole-Cl, to suppress LPS induction of IL-6 mRNA in BV2 cells. Cells were pretreated with the indicated ligands for 1 hr except for DHEA, which was added 6 hr prior to LPS stimulation. *p < 0.01 compared to EtOH treated and LPS stimulated sample. Error bars represent SD. See also Figure S4 . (Simard et al., 2005) . Mouse and human microglia express most of the 17b-HSDs to variable extents ( Figures S4A and S4B , respectively). Among these, HSD17B14 is highly expressed and is located on human chromosome 19q13, which has been identified as an MS susceptible locus (Bonetti et al., 2009; Wise et al., 1999) . 17b-HSD type 14 (HSD17B14) is a newly identified member of the 17b-HSD family initially shown to covert estradiol to estrone (Lukacik et al., 2007) . To investigate whether HSD17B14 is also able to convert DHEA to ADIOL, COS-1 cells that do not exhibit endogenous activity to convert DHEA to ADIOL ( Figure 4B , left column) were transiently transfected with expression vectors for HSD17B1 or HSD17B14. Then cells were pulsed with DHEA and conversion to metabolites was monitored over time by gas chromatography (GC). Expression of HSD17B1 efficiently catalyzed conversion of DHEA to a product that exhibited an identical retention time to that of an ADIOL standard, consistent with the previously established enzymatic activity of HSD17B1 ( Figure 4B , middle panel). As shown in Figure 4B (right column), expression of HSD17B14 at similar proteins levels (Figure S4C ) generated a product with an identical retention time with similar efficiency. Importantly, the supernatants from HSD17B1 and B14-expressing cells, but not from mock-transfected cells, repressed the expression of IL-6 upon LPS stimulation in BV2 microglia cells in a manner similar to that of ADIOL ( Figure S4D) . Next, to investigate whether HSD17B14 might contribute to conversion of DHEA into ADIOL in microglia cells, we generated stable BV2 microglia cell lines expressing specific short hairpin RNAs (shRNAs) against HSD17B14 (shHSD17B14), HSD17B1 (shHSD17B1) or scramble control (shCtrl) using lentivirus vectors ( Figure S4E ). Knockdown of HSD17B14, but not HSD17B1, significantly reduced the conversion of DHEA to ADIOL (Figure 4C ). In addition, knockdown of HSD17B14 resulted in greatly exaggerated responses to LPS and abolished the ability of DHEA to suppress LPS induction of IL-6 mRNA ( Figure 4D ). In contrast, ADIOL and Indazole-Cl suppressed LPS induction of IL-6 in all three cell lines. Collectively, these findings suggest that HSD17B14 can efficiently catalyze the production of ADIOL from DHEA in microglia cells.
To further investigate the role of HSD17B14 in controlling ERb activity in microglia, we compared the consequences of knocking down HSD17B14, HSD17B1 and ERb on the magnitude and duration of the response to LPS. Knockdown of ERb and HSD17B14, but not HSD17B1, increased and prolonged the induction of IL-23p19 ( Figure 5A ) and IL-6 ( Figure S5A ) mRNAs. Notably, HSD17B14 mRNA expression was downregulated in mouse and human microglia by LPS treatment (Figures 5B and 5C ). Consistent with this, ADIOL conversion was decreased following LPS stimulation of microglia cells ( Figure 5D ). Expression of HSD17B14 was also downregulated by IL-1b in mouse and human astrocytes ( Figures S5C and S5D, respectively) . Conversely, LPS induced expression of the major 3b-HSDs expressed in mouse and human microglia ( Figures S5D and  S5E) . Interestingly, the anti-inflammatory cytokine IL-10 upregulated the expression of HSD17B14 in mouse and human microglia ( Figures 5E and 5F ). The observation that 17b-estradiol inefficiently induced anti-inflammatory activities of ERb in microglia and astrocytes, but binds to ERb with a higher affinity than ADIOL (Kuiper et al., 1997) raised the possibility that it could antagonize ERb-mediated repression of inflammatory response genes. Consistent with this possibility, 17b-estradiol inhibited ADIOL suppression of IL-6 induction, with an IC 50 value of $0.1 mM, in accord with the relative affinities of 17b-estradiol and ADIOL for ERb ( Figure 5G ).
ERb-Mediated Repression Is Initiated by Tethering to cFos
A major question raised by these observations was the molecular basis for differential activities of 17b-estradiol and the Indazoles and ADIOL. Nuclear receptors can act as transcriptional repressors by direct interactions with specific DNA sequences in target genes or by transrepression mechanisms involving tethering to other transcription factors that are specifically bound to target gene promoters . To test which of these was used by ERb to suppress inflammatory response genes, we mutated the DNA binding domain (DBD) of ERb so that it could not bind to estrogen responsive element (ERE) sequences. RAW264.7 cells were transfected with wild-type ERb or DBD mutant expression plasmids together with siRNAs directed against ERa to prevent any spurious effects of ERa. The DBD mutant of ERb was unable to activate an ERE-luciferase reporter gene as expected ( Figure S6A ), but was able to repress induction of iNOS-luciferase by LPS ( Figure 6A ), consistent with a transrepression mechanism. Next, we looked for potential transcription factors that ERb could tether to on target gene promoters. Among the factors evaluated, ERb was found to coimmunoprecipitate with cFos upon LPS stimulation in BV2 cells ( Figure 6B ). Chromatin immunoprecipitation (ChIP) assays demonstrated that ERb and cFos were recruited to the IL-23p19 promoter in BV2 cells in response to LPS ( Figure 6C ). ERb was not recruited to the promoter in cFos knockdown BV2 cells ( Figure S6B ), consistent with a tethering-dependent mechanism.
We next investigated specific signals that might be required for inducing this interaction. cFos is known to be phosphorylated by several kinases such as ERK, RSK and IKKb and protein kinase A (PKA) (Koga et al., 2009; Piechaczyk and Blanchard, 1994) . Surprisingly, LPS treatment of microglia induced phosphorylation of cFos at sites that could be detected with an anti-phospho-PKA substrate antibody ( Figure 6D ), implicating phosphorylation by PKA. Consistent with this observation, LPS stimulation induced the activation of PKA in microglia cells ( Figure S6C ). IL-1b and CpG DNA also activated PKA, while polyI:C did not ( Figure S6E ), suggesting involvement of the MyD88 pathway. To investigate whether PKA activity was important for ERb-mediated repression, we established microglia cell lines in which shRNAs were used to knock down expression of the two catalytic subunits of PKA, Ca and Cb (Wall et al., 2009) . As shown in Figure 6E , knockdown of the catalytic subunits of PKA abolished Indazole-mediated repression of IL-6. Similarly, the stimulation-dependent binding of cFos and ERb was abolished in these cells ( Figure 6F ). Finally, we identified serine 362 (S362) as the main residue in cFos targeted by PKA-phosphorylation and mutated this residue into alanine to prevent phosphorylation (S362A) or to glutamate to mimic constitutive phosphorylation (S362E). The cFos S362A mutant exhibited impaired stimulation-dependent binding to ERb, while the S362E mutant exhibited constitutive interaction ( Figure 6G ). These results suggest that ERb-mediated repression of proinflammatory mediators in microglia is initiated by tethering (G) Phosphorylation of cFos at S362 is required for LPS-induced interaction with ERb. Lentivirus carrying HA-tagged wild-type (WT), S352A and S362E mutant cFos were infected into BV2 cells. Cells were stimulated with LPS for 30 min and whole cell extracts were analyzed by immunoprecipitation with a -ERb antibody and western blotting for HA. See also Figure S6 .
of ERb to cFos in a PKA-mediated phosphorylation-dependent manner.
Ligand-Specific Recruitment of CtBP to ERb Mediates Transrepression
Transrepression functions of nuclear receptors have previously been documented to involve prevention of corepressor removal or corepressor recruitment . Therefore, we next performed an siRNA screen to search for corepressors that might be required for ERb transrepression activity in microglia cells. In this screen, siRNAs directed against either C-terminal binding protein (CtBP)1 or 2 were found to revert Indazole-mediated repression of IL-23p19 ( Figure 7A ) and ADIOL-mediated repression of IL-6 ( Figure S7A ). Thus, we speculated that ERb recruits CtBP corepressor complexes upon ligand treatment. To confirm whether CtBP was recruited to the target gene promoters, we performed ChIP assay at the IL-23p19 and IL-6 promoter. LPS alone or Indazole alone did not recruit CtBP at the promoter region, but both LPS and Indazole ( Figure 7B and Figure S7B ) or ADIOL ( Figures S7C and  S7D ) induced the recruitment of CtBP at the promoter region. To confirm whether ERb is required for the recruitment of CtBP to the promoter, we performed ChIP assay in BV2 cells infected the lentivirus carrying specific shRNA against ERb (shERb). As shown in Figure 7C , the recruitment of CtBP was abolished in shERb cells upon LPS and Indazole treatment, suggesting that ERb is acting as a beacon for CtBP. Importantly, CtBP could be coimmunoprecipitated with ERb in microglia cells that were stimulated by Indazole-Cl and ADIOL, which induced the repressive function of ERb, but not by 17b-estradiol, which did not stimulate transrepression activity of ERb in microglia ( Figure 7D ). Although LPS stimulation was required to promote interaction of ERb with cFos, it was not required for the interaction between ERb and CtBP in microglia ( Figure 7D ). These observations suggest that the selective ability of Indazole-Cl/Br and ADIOL to recruit CtBP complexes to ERb provides a molecular explanation for their differential effects on inflammatory gene expression.
DISCUSSION
ERa and ERb activate target genes in response to 17b-estradiol and both are considered to be physiologic estrogen receptors (Minutolo et al., 2009; Pettersson and Gustafsson, 2001) . Although ERa and ERb have highly conserved DNA binding domains, recent studies have shown that there are significant differences in the chromatin binding sites that they occupy upon stimulation by 17b-estradiol or other hormonal ligands and the genes that they regulated (Chang et al., 2008; Grober et al., 2011) . In addition, variation in their respective ligand-binding cavities confers overlapping but distinct ligand-binding properties (Kuiper et al., 1997; Minutolo et al., 2009 ). These differences have been exploited for the development of numerous synthetic ligands that exhibit marked preferences for binding to ERa or ERb (Minutolo et al., 2009) . In most cases, functional evaluation of these ligands has been carried out to characterize their ability to positively regulate estrogen-responsive reporter genes (Meyers et al., 2001; Stauffer et al., 2000) or endogenous genes (Chang et al., 2008) . The present studies are based on the serendipitous observation that two ERb-specific ligands based on a halogen-substituted phenyl-2H-indazole core (De Angelis et al., 2005) potently suppressed transcriptional activation of TLR4-responsive genes in microglia, while 17b-estradiol and, in particular, a number of other ERb-selective ligands did not. Notably, Indazole-Br and Indazole-Cl suppressed production of cytokines by activated microglia and astrocytes that promote Th17 cell differentiation and activation, and Indazole-Cl potently inhibited signs of EAE in mice in an ERb-dependent manner and reversed established disease.
These findings raised the question of whether Indozole-Br and Indazole-Cl might be mimicking the activities of endogenous sterols other than 17b-estradiol that function to regulate the transrepression activities of ERb. Studies of endogenous steroids that are known to bind to ERb (Kuiper et al., 1997) resulted in the identification of ADIOL and a small set of other naturally occurring and synthetic steroids as also being able to repress induction of proinflammatory cytokines in microglia, raising the possibility of ERb-dependent anti-inflammatory roles of these molecules in vivo. Potential functional roles of ADIOL are of particular interest because of extensive prior work documenting its biosynthesis in microglia (Jellinck et al., 2007) and linkage of genetic variation in the vicinity of the 17b-HSD type 14 locus to risk of Multiple Sclerosis (Bonetti et al., 2009; Wise et al., 1999) .
A working model for how ERb could act as a transcriptional repressor is illustrated in Figure 7E . First, inflammatory stimuli such as LPS induce binding of cJun/cFos AP-1 heterodimers to inflammatory responsive genes. PKA is coordinately activated in a MyD88-dependent manner and induces the phosphorylation of cFos, providing a docking site for ERb. Binding of IndazoleBr/Cl or ADIOL to ERb induces interaction of the CtBPrepressor, resulting in transcriptional repression. This proposed transrepression mechanism is functionally analogous to transrepression mechanisms utilized by the glucocorticoid receptor (Rogatsky et al., 2002) and Nurr1 (Saijo et al., 2009 ) to recruit GRIP and CoREST corepressor complexes, respectively, to transcriptionally active promoters. Thus, the ERb pathway functions as a negative feedback mechanism to attenuate transcription from active promoters.
CtBP complexes can also be used to mediate active repression by ERa at a subset of estrogen response elements (Stossi et al., 2009) . A key question is therefore to understand the mechanisms and specificity of recruitment of the CtBP complex. The present studies indicate that Indazole-Br/Cl and ADIOL function as selective ERb modulators that effectively promote interaction with this complex. The inability of 17b-estradiol to induce CtBP interaction therefore provides a molecular explanation for the differential effects of Indazoles and ADIOL versus 17b-estradiol as inhibitors of inflammatory response genes in microglia. It will be of considerable interest to define the structural differences imposed by these ligands on the ERb ligand domain and how these differences are ultimately interpreted by components of the CtBP complex. CtBP frequently interacts with target proteins through a PXDLS motif (Schaeper et al., 1998) , but ERb does not have this motif. Therefore, alternative linker proteins are likely to be involved in bridging ERb and CtBP in ligand-dependent manner, possibly involving post-translational modifications. Further studies will be required to establish the precise mechanisms of interaction.
Overall, our data suggest that in addition to being a receptor for 17b-estradiol, ERb is a physiologic receptor for ADIOL that is produced in an autocrine manner by microglia (Jellinck et al., 2007) , and potentially astrocytes. Although, the concentration of ADIOL in the brain is not clear at this moment, knockdown of HSD17B14 in microglia cells cultured in 10% serum resulted in an exaggerated inflammatory response. This result suggests that the concentrations of serum-derived DHEA provide substrate for synthesis of sufficient ADIOL to suppress inflammatory responses. The findings that HSD17B14 and HSD3Bs are reciprocally regulated by LPS and that HSD17B14 is positively regulated by the anti-inflammatory cytokine IL-10 suggests that in the setting of acute infection or injury, the ADIOL pathway is rapidly downregulated to allow an effective inflammatory response to occur. Upon eradication of the inciting stimulus, anti-inflammatory cytokines such as IL-10 induce expression of HSD17B14, which by activating the ERb/CtBP pathway, could promote resolution of inflammation and re-establishment of the de-activated phenotypes of microglia and astrocytes, in concert with other resolution pathways. The finding that 17b-estradiol can antagonize the anti-inflammatory activities of ADIOL provides another level by which the ADIOL pathway might be controlled, and could help explain some of the complexity of estrogen activity in the brain and the increased susceptibility of females to Multiple Sclerosis.
The ability of Indozole-Cl to induce remission of EAE after clinical signs have developed suggests new points of therapeutic intervention in neurodegenerative diseases in which inflammation plays a pathogenic role. Prior studies of the ERb-selective ligand DPN in EAE demonstrated limited benefit that was unrelated to inflammation (Tiwari-Woodruff et al., 2007) , consistent with our finding that it does not promote entry of ERb into the CtBP-dependent transrepression pathway. This, together with our finding that DPN and another ERb-selective ligand, ERB-041, were inactive in repressing activation of inflammatory response genes in microglia that were inhibited by Indazoles, indicates that ligands that are ERb-selective but have somewhat different structures can have surprisingly different activities. Although not widely documented, this compound-specific activity of different ERb-selective ligands appears to be an emerging trend (Minutolo et al., 2009) . Therefore, the development of ERb-specific ligands that are optimized for this activity might be of therapeutic benefit in diseases driven by dysfunction of the innate and adaptive immune systems.
EXPERIMENTAL PROCEDURES
Mice C57BL/6 mice were obtained from Charles River and ERb À/À mice were purchased from Jackson laboratory. All animal housing and experiments were approved by IACUC at UCSD.
Cell Culture
Primary human microglia and astrocytes were obtained from Clonexpress and Sciencell, respectively. COS-1 cells were purchased from ATCC. Primary mouse microglia and astrocytes were obtained and cultured as described before (Saijo et al., 2009) . To treat the cells with various ERb ligands, cells were cultured in DMEM without Phenol-red (Invitrogen) supplemented with 10% Charcoal/Dextran-stripped FBS (Hyclone) for 24 hr in prior to the pretreatment. Then, cells were incubated with the indicated ligands at the final concentration of 1 mM unless otherwise noted for 1 hr followed by 0.1 mg/ml LPS (E. coli 0111:B4, Sigma) to microglia or 10ng/ml IL-1b (R & D system) to astrocytes for indicated time. See Extended Experimental Procedures for other cells.
Reagents
All smart-pool siRNAs and GIPZ or pLKO.1 shRNA containing lentivirus were purchased from Dharmacon and OpenBiosystems, respectively. Retrovirus carrying shRNA against the PKA a and b catalytic subunits was kindly provided by Mel Simon. Commercially available ERb ligands were purchased from Steraloids.
Chromatin Immunoprecipitation Assays 2 3 10 7 BV2 cells were used for ChIP as described before (Saijo et al., 2009 ).
Anti-ERb (L-20 and H-150), anti-cFos (H-125 and 4) and anti-CtBP1/2 (E-12) were purchased from Santa Cruz biotechnology.
RNA Isolation and Quantitative PCR Total RNA was isolated by RNAeasy kit (QIAGEN) from cells. One microgram of total RNA was used for cDNA synthesis using Superscript III (Invitrogen), and quantitative PCR was performed with SYBR-GreenER (Invitrogen) detected by 7300 Real Time PCR System (ABI). The sequences of qPCR primers used for mRNA quantification in this study were obtained from PrimerBank (Spandidos et al., 2010) .
Experimental Autoimmune Encephalomyelitis
Osmotic pumps (Alzet) with ligands or vehicle were implanted under the skin 2 days before EAE induction or after the clinical score developed at 1. 8-12 weeks age-matched mice were used for the experiment based on the standard protocol (Stromnes and Goverman, 2006) . See Extended Experimental Procedures for detailed protocols.
Gas Chromatography
For GC determination, steroids were extracted from 1 ml of media and 25 mg of androsterone (Steraloids) added as an internal standard using the method by Gottfried-Blackmore et al. with minor modifications (Gottfried-Blackmore et al., 2008) . Samples were loaded onto a Shimadzu GC-2014 gas chromatogram using a 30 m 3 0.25 mm (i.d.) ZB-5HT inferno capillary column (film thickness 0.2 mm) (Phenomenex). See Extended Experimental Procedures for detailed protocols.
Statistical Analyses
Standard deviation (SD), two-tail Student's t test and ANOVA were performed with the Prism 5 program. p < 0.01 was considered significant. All data are presented as mean ± SD.
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